4.6 Editorial Material

Reply to Interpretation of Pharmacovigilance Disproportionality Analyses

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Letter Pharmacology & Pharmacy

Interpretation of Pharmacovigilance Disproportionality Analyses

Charles Khouri et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

COVID-19 Vaccination and the Incidence of De Novo or Recurrent Rheumatoid Arthritis: A French and International (VigiBase) Signal Detection Study

Viktoryia Prontskus et al.

Summary: COVID-19 vaccination does not pose a higher risk of rheumatoid arthritis (RA) compared with other nonlive vaccines. Cases of new-onset RA or flare-ups in individuals with pre-existing RA were reported in pharmacovigilance databases. The majority of RA cases occurred after the first dose and the time between vaccination and disease onset was shorter in the flare-up group.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Health Care Sciences & Services

Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases

Charles Khouri et al.

Summary: This study aimed at testing the correlation between adverse drug reactions relative risks estimated from meta-analyses and disproportionality analyses calculated from pharmacovigilance spontaneous reporting systems databases. While a significant correlation was found for some ADRs, the agreement was poor and relative bias was important.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)